GB2553684A - Ethynylxanthines, preparation and use for cancer treatment - Google Patents

Ethynylxanthines, preparation and use for cancer treatment Download PDF

Info

Publication number
GB2553684A
GB2553684A GB1714548.3A GB201714548A GB2553684A GB 2553684 A GB2553684 A GB 2553684A GB 201714548 A GB201714548 A GB 201714548A GB 2553684 A GB2553684 A GB 2553684A
Authority
GB
United Kingdom
Prior art keywords
ethynylxanthines
preparation
cancer treatment
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB1714548.3A
Other versions
GB2553684A8 (en
GB2553684B (en
Inventor
Arsenjans Pavels
Vasiljeva Jelena
Domracheva Llona
Shestakova Irina
Gulbe Anita
Kauss Valerjans
Kalvins Ivars
Kanepe Lapsa Iveta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Latvian Institute of Organic Synthesis
Original Assignee
Latvian Institute of Organic Synthesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvian Institute of Organic Synthesis filed Critical Latvian Institute of Organic Synthesis
Publication of GB2553684A publication Critical patent/GB2553684A/en
Publication of GB2553684A8 publication Critical patent/GB2553684A8/en
Application granted granted Critical
Publication of GB2553684B publication Critical patent/GB2553684B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel ethynylxanthine derivatives of formula (I) which exhibit high antiproliferative activity against various tumor cell lines, methods for their synthesis and use for the treatment and/or prevention of cancer.

Description

(54) Title of the Invention: Ethynylxanthines, preparation and use for cancer treatment Abstract Title: Ethynylxanthines, preparation and use for cancer treatment

Claims (1)

  1. The present invention relates to novel ethynylxanthine derivatives of formula (I) which exhibit high antiproliferative activity against various tumor cell lines, methods for their synthesis and use for the treatment and/or prevention of cancer.
    I
GB1714548.3A 2015-03-27 2015-03-27 Ethynylxanthines, preparation and use for cancer treatment Active GB2553684B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/LV2015/000001 WO2016159745A1 (en) 2015-03-27 2015-03-27 Ethynylxanthines, preparation and use for cancer treatment

Publications (3)

Publication Number Publication Date
GB2553684A true GB2553684A (en) 2018-03-14
GB2553684A8 GB2553684A8 (en) 2018-04-18
GB2553684B GB2553684B (en) 2020-06-03

Family

ID=52815227

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1714548.3A Active GB2553684B (en) 2015-03-27 2015-03-27 Ethynylxanthines, preparation and use for cancer treatment

Country Status (3)

Country Link
CA (1) CA2989161C (en)
GB (1) GB2553684B (en)
WO (1) WO2016159745A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077557A1 (en) * 2006-12-22 2008-07-03 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective a2a receptor antagonists
WO2009024542A2 (en) * 2007-08-17 2009-02-26 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
WO2011005871A1 (en) * 2009-07-07 2011-01-13 Pgxhealth, Llc Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2166948C1 (en) 2000-05-29 2001-05-20 Центральный научно-исследовательский рентгенорадиологический институт Method for treating gliomae aggravated with epileptic syndrome
NZ711718A (en) 2013-03-15 2020-05-29 Hydra Biosciences Llc Substituted xanthines and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077557A1 (en) * 2006-12-22 2008-07-03 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective a2a receptor antagonists
WO2009024542A2 (en) * 2007-08-17 2009-02-26 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
WO2011005871A1 (en) * 2009-07-07 2011-01-13 Pgxhealth, Llc Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (20060712), Database accession no. 892164-23-7, XP002739192 *

Also Published As

Publication number Publication date
WO2016159745A1 (en) 2016-10-06
CA2989161C (en) 2022-03-01
GB2553684A8 (en) 2018-04-18
GB2553684B (en) 2020-06-03
CA2989161A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
MX2020013649A (en) Compositions and methods for inhibiting arginase activity.
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MY196749A (en) Eif4a-inhibiting compounds and methods related thereto
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
MX2018005019A (en) Benzofuran derivative, preparation method thereof and use thereof in medicine.
WO2015101958A3 (en) Inhibitors of glutaminase
TN2018000119A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
WO2015033228A3 (en) Compounds and use for treating cancer
WO2017027359A8 (en) Pyridines and their use in the treatment of cancer
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
SA520411726B1 (en) Novel Phenylpyridine Derivative and Pharmaceutical Composition Comprising The Same
MX2021011699A (en) Quinoline derivatives and their use for the treatment of cancer.
GB2553684A (en) Ethynylxanthines, preparation and use for cancer treatment
WO2019040104A3 (en) Compounds, salts thereof and their use for the treatment of diseases
WO2016100833A3 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
WO2015128873A9 (en) "6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors"
IN2013DE03665A (en)
EA201992557A1 (en) ANTITUMOR COMPOUNDS
MX2020000491A (en) Therapeutic modulators of the reverse mode of atp synthase.